In the present study, we directly compared DNA methylation of nine selected genes in CTCs and paired plasma-cfDNA of NSCLC patients that are longitudinally monitored during osimertinib therapy, to evaluate a potential role in NSCLC progression and EGFR TKI therapy resistance. This evidence concerns the gene EGFR and non-small cell lung carcinoma.